West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
IceCure Medical (ICCM) received IRB approval from West Cancer Center for its ChoICE study on ProSense® cryoablation for low-risk breast cancer. The study, expected to enroll patients soon, aims to gather real-world data on the treatment. ProSense® is FDA-approved for women 70+ with low-risk tumors. The study will involve 30 sites and 400 patients, expanding access to cryoablation.
How this was made
The 30-second read
Why it matters
The IRB approval enables real‑world data collection, which could validate the device's efficacy and drive broader adoption.
Market read
First‑report of a regulatory milestone for a niche med‑tech firm; may influence its stock and the cryoablation market.
What to watch
Potential competition from alternative ablation technologies and reimbursement uncertainties could temper upside.
Background
IceCure Medical's ProSense® system is the only FDA‑cleared cryoablation device for low‑risk breast cancer in women 70+. The ChoICE study will enroll up to 400 patients across 30 sites.
Ticker impact
IceCure Medical received IRB approval to start the ChoICE post‑marketing study for its ProSense® breast‑cancer cryoablation device.
Potential modest upside as the study enrollment begins, with longer‑term upside if data are favorable.
IRB approval is a concrete new development, but commercial impact depends on patient enrollment and future trial results.
Market effects
May reinforce interest in minimally invasive cryoablation technologies across the med‑tech sector.
Highlights growth of breast‑cancer treatment options in the U.S. Midwest.
Supports broader adoption of cryoablation devices worldwide as more data become available.
Counterpoint
If enrollment lags or data are inconclusive, the approval could be a non‑event with limited price impact.
Key entities
- CompanyIceCure Medical Ltd.
Developer of the ProSense® cryoablation system.
- InstitutionWest Cancer Center & Research Institute
Site of the IRB approval and study enrollment.
